NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Sell
36
CNSP Quote, Financials, Valuation and Earnings
Last price:
$0.11
Seasonality move
:
-46.41%
Day range:
$0.10 - $0.12
52-week range:
$0.10 - $70.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.90x
Volume:
4.6M
Avg. volume:
7.3M
1-year change:
-99.78%
Market cap:
$6.4M
Revenue:
--
EPS (TTM):
-$70.72
Analysts' Opinion
-
Consensus RatingCNS Pharmaceuticals has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, CNS Pharmaceuticals has an estimated upside of 350.45% from its current price of $0.11.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $0.11.
Fair Value
-
According to the consensus of 0 analysts, CNS Pharmaceuticals has 350.45% upside to fair value with a price target of -- per share.
CNSP vs. S&P 500
-
Over the past 5 trading days, CNS Pharmaceuticals has overperformed the S&P 500 by 10.06% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
CNS Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
CNS Pharmaceuticals has grown year-over-year revenues for 0 quarters straight. In the most recent quarter CNS Pharmaceuticals reported revenues of --.
Earnings Growth
-
CNS Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter CNS Pharmaceuticals reported earnings per share of -$0.25.
Enterprise value:
-560.9K
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.04x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$13.4M | -$18.6M | -$17.1M | -$4.5M | -$5.6M | |
| EBITDA | -$13.4M | -$18.6M | -$17M | -$4.5M | -$5.6M | |
| Diluted EPS | -$563.50 | -$413.00 | -$70.72 | -$54.14 | -$0.25 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.5M | $11.2M | $8.7M | $2.1M | $7.4M | |
| Total Assets | $3M | $11.5M | $9.6M | $2.3M | $7.4M | |
| Current Liabilities | $510.8K | $2.4M | $1.2M | $4.1M | $4.1M | |
| Total Liabilities | $510.8K | $2.4M | $1.2M | $4.1M | $4.1M | |
| Total Equity | $2.5M | $9.1M | $8.4M | -$1.7M | $3.4M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$11.5M | -$13.9M | -$14.2M | -$3.4M | -$6.8M | |
| Cash From Investing | -- | -- | -- | -$1.7K | -- | |
| Cash From Financing | $10.2M | $7.8M | $20.2M | $8.4K | $12.3M | |
| Free Cash Flow | -$11.5M | -$13.9M | -$14.2M | -$3.4M | -$6.8M | |
CNSP
Sector
Market Cap
$6.4M
$43.9M
Price % of 52-Week High
0.16%
45.73%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-99.78%
-29.11%
Beta (5-Year)
1.067
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$0.11
200-day SMA
Sell
Level
$4.42
Bollinger Bands (100)
Sell
Level
0.11 - 0.17
Chaikin Money Flow
Sell
Level
-958.2M
20-day SMA
Sell
Level
$0.11
Relative Strength Index (RSI14)
Sell
Level
47.71
ADX Line
Sell
Level
11.09
Williams %R
Neutral
Level
-47.7816
50-day SMA
Sell
Level
$0.12
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Sell
Level
-40
On Balance Volume
Sell
Level
-280.5M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
Stock Forecast FAQ
In the current month, CNSP has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CNSP average analyst price target in the past 3 months is --.
-
Where Will CNS Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that CNS Pharmaceuticals share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About CNS Pharmaceuticals?
Analysts are divided on their view about CNS Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that CNS Pharmaceuticals is a Sell and believe this share price will drop from its current level to --.
-
What Is CNS Pharmaceuticals's Price Target?
The price target for CNS Pharmaceuticals over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CNSP A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for CNS Pharmaceuticals is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CNSP?
You can purchase shares of CNS Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase CNS Pharmaceuticals shares.
-
What Is The CNS Pharmaceuticals Share Price Today?
CNS Pharmaceuticals was last trading at $0.11 per share. This represents the most recent stock quote for CNS Pharmaceuticals. Yesterday, CNS Pharmaceuticals closed at $0.11 per share.
-
How To Buy CNS Pharmaceuticals Stock Online?
In order to purchase CNS Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is up 3.65% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 4.9% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 4.4% over the past day.
